Welcome to our dedicated page for P3 HEALTH PARTNERS SEC filings (Ticker: PIIIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The P3 Health Partners Inc. PIIIW SEC filings page provides access to the company’s regulatory disclosures related to its warrants and broader corporate activities. According to recent Forms 8-K, P3 Health Partners Inc. is the registrant for warrants exercisable for one share of Class A common stock listed on The Nasdaq Stock Market LLC under the symbol PIIIW. These filings also describe key aspects of the company’s capital structure, governance and financing arrangements.
For investors and researchers, core documents include current reports on Form 8-K that outline material events such as amendments to the company’s term loan agreement and changes in board composition. One 8-K details a Tenth Amendment to a term loan agreement for subsidiary P3 Health Group, LLC, addressing the interest-only period, maturity date, interest rate structure, paid-in-kind interest options and lender board observation rights. Another 8-K reports the resignation of a director and the appointment of a new director who also serves as Chief Executive Officer.
In addition to 8-Ks, P3’s periodic reports contain discussions of non-GAAP measures like Adjusted EBITDA and Adjusted EBITDA per member per month (PMPM), as well as key performance metrics such as at-risk Medicare Advantage membership. These filings explain how the company evaluates operating performance within its population health management and value-based care model.
On Stock Titan, users can review these SEC filings with AI-powered summaries that highlight important terms, capital structure changes and governance updates. Real-time updates from EDGAR, along with simplified explanations of complex sections, help readers interpret how developments disclosed in 10-K, 10-Q, 8-K and Form 4 filings may relate to the PIIIW warrants and the underlying P3 Health Partners Inc. business.
Mary A. Tolan, a director of P3 Health Partners Inc., was granted 2,000 restricted stock units (RSUs) under the company 2021 Incentive Award Plan on 08/06/2025. Each RSU represents a right to receive one share of Class A common stock and the awards vest one year from the grant date. The grant was recorded with a reported price of $0. After the issuance, Ms. Tolan beneficially owns 218,561 shares of Class A common stock in a direct ownership form. The transaction was reported on a Form 4 as an acquisition by a reporting person who is a director.
P3 Health Partners reported that director Mark Thierer was granted 4,000 restricted stock units (RSUs) under the company’s 2021 Incentive Award Plan, with the award recorded on 08/06/2025. Each RSU represents the right to receive one share of Class A common stock and the RSUs vest in one year from the grant date, meaning the shares will be issued if the vesting conditions are met. The filing shows the RSUs were issued at no cash price and increased Thierer’s reported beneficial ownership to 437,121 shares, held directly. No derivative securities were reported in this filing.
P3 Health Partners Inc. director Gregory D. Wasson received a grant of 2,000 restricted stock units (RSUs) on 08/06/2025 reported on a Form 4. The RSUs were granted under the 2021 Incentive Award Plan and each RSU represents the right to receive one share of Class A common stock. The award carries a $0 price and vests one year from the grant date. Following the reported transaction, Mr. Wasson is shown as beneficially owning 218,561 shares directly. The filing was signed by an attorney-in-fact on 08/08/2025.
P3 Health Partners Inc. reported a director-level equity award: Jeffrey G. Park was granted 2,000 restricted stock units (RSUs) under the company's 2021 Incentive Award Plan. Each RSU represents a right to receive one share of Class A common stock and the RSUs vest one year from the grant date. The grant was recorded as an acquisition at a $0 price and the filing shows 218,561 shares beneficially owned by the reporting person following the award, held in a direct form of ownership. This filing documents a routine equity-based compensation event for a director, specifying award mechanics and post-grant holdings.
P3 Health Partners Inc. (PIII) Form 4 summary: Director Leisure Lawrence B. was granted 2,000 restricted stock units (RSUs) on 08/06/2025 under the P3 Health Partners 2021 Incentive Award Plan. Each RSU represents a right to receive one share of Class A common stock and the RSUs vest one year from the grant date. The grant was recorded at a $0 price. Following the reported transaction, the reporting person beneficially owned 218,561 Class A shares. The Form 4 lists the reporting person as a director and was signed by an attorney-in-fact on 08/08/2025.
P3 Health Partners Inc. Director Thomas Edmunds Price was granted 2,000 restricted stock units (RSUs) on 08/06/2025. Each RSU represents a right to receive one share of Class A common stock and the award vests one year from the grant date, meaning delivery of shares occurs only after vesting. The grant was made under the company’s 2021 Incentive Award Plan and shows an acquisition at no cash price.
After the grant, the filing reports 218,561 shares beneficially owned by the reporting person on a direct basis. This transaction is a typical equity-based compensation award to a director and does not reflect an immediate sale or transfer of issued shares.